Research Staff, LLMs
DeepgramFull Time
Expert & Leadership (9+ years)
Toronto, Ontario, Canada
Key technologies and capabilities for this role
Common questions about this position
Candidates need an MSc or PhD in Computer Science, Computational Biology, Bioinformatics, or a related field, plus 3+ years of hands-on experience architecting and building complex applications using Large Language Models, along with expert knowledge of Python and modern MLOps frameworks.
The ideal candidate has 3+ years of experience in using and developing solutions using LLMs for complex, multi-agent workflows, a background in genomics or computational biology, and clear experience in MLOps and architecting agentic solutions.
The multidisciplinary team is based in Toronto and Cambridge, MA.
You will interact closely with the machine learning team developing foundation models, the engineering and infrastructure teams to build scalable systems, and the statistical genetics and experimental groups, while working within the Systems and Target Biology group.
A strong candidate is passionate about leveraging AI and foundation models to disrupt therapeutic design workflows, adept at translating complex scientific requirements into robust computational solutions, and has a background in genomics or computational biology.
AI-driven drug discovery and development
Deep Genomics focuses on drug development in the biotechnology sector by utilizing artificial intelligence to explore RNA biology and discover potential therapies for genetic conditions. The company's main product, the AI Workbench, employs data-driven predictions to identify new drug targets. This tool has evolved over time, with the latest version, AI Workbench 3.0, set to enhance its capabilities in targeting complex genetic diseases. Deep Genomics serves a diverse clientele, including pharmaceutical companies and research institutions, and generates revenue through the development and licensing of its AI Workbench. The goal of Deep Genomics is to accelerate the drug discovery process and improve treatment options for patients suffering from genetic disorders.